Regulatory News · July 27, 2026
FDA Advisory Committee Recommended Six Peptides for 503A Review
In July 2026, an FDA advisory committee gave favorable recommendations to six of seven peptides considered for possible 503A Bulks List inclusion.
Published by PeptideSchool Editorial Team
What happened at the July meeting
On July 23 and 24, 2026, the FDA Pharmacy Compounding Advisory Committee considered seven peptide substances for possible inclusion on the Section 503A Bulks List. Six received favorable recommendations: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide, also known as DSIP, did not receive a favorable recommendation.
The recorded votes were 8 to 6 for BPC-157, 8 to 6 for KPV, 8 to 6 for TB-500, 7 to 5 for MOTS-c, 8 to 5 for Semax, and 7 to 4 for Epitalon. Emideltide received an unfavorable 6 to 7 result. Several votes were close, so the outcome reflects a divided advisory judgment rather than broad consensus.
What the recommendations do not mean
Advisory committee votes are nonbinding. They do not approve any peptide as a drug, establish clinical effectiveness, authorize every compounded product, or create immediate unrestricted access. FDA staff had recommended against adding all seven substances, citing concerns that included limited human evidence, uncertain safety, potential immunogenicity, and gaps in manufacturing and product-quality information.
Section 503A addresses traditional pharmacy compounding under specific federal conditions. Possible Bulks List inclusion is not the same as approval of a finished drug for a particular condition.
What happens next
FDA must evaluate the committee record and complete the regulatory process required for any final Bulks List action. Until the agency acts, the recommendations do not by themselves change approval or legal status. Timing and final outcomes remain uncertain.
The meeting is important because it moved a public regulatory discussion forward despite significant evidence gaps. The appropriate response is to follow the next agency documents and source record, not to treat advisory momentum as proof of safety or effectiveness.
Educational content only. Not medical advice.
Sources
- FDA PCAC meeting page, July 23-24, 2026
- FDA meeting materials and staff review
- ABC News: FDA advisers narrowly vote to add six peptides to compounding list
- STAT: Panel backs Epitalon and rejects Emideltide
- RAPS: Advisory committee backs two more peptides and rejects one
- BioPharma Dive: FDA panel endorses broader use of certain peptides
Educational content only. Not medical advice.